Switzerland's Lonza, one of the leading contract manufacturers of
active pharmaceutical ingredients, has forged a collaboration with
RNA-TEC of Belgium to provide broad-ranging contract production of
oligonucleotides, a new class...
Scientists at the Cold Spring Harbor Laboratory in the US have
developed what they claim is the first full library of human RNA
interference (RNAi) clones, enabling researchers to shut down
virtually any gene of interest in the human...
US company NeoPharm believes it may have overcome one of the major
limitations of using RNA interference (RNAi) or gene silencing as a
systemic treatment.
An application that will enable direct measurement of nucleic acids
without the need for amplification has been developed by US
Genomics. The application will also allow researchers to perform
validation and characterization of specific...
Since the sequencing of the human genome, there has been a lot of
attention paid to finding cellular factors that control gene
expression. Micro RNA (miRNA) - small sequences of 20-24
nucleotides that do not code for proteins - are...
Fisher Scientific International has swooped on two companies
providing tools for life sciences companies in a move designed to
boost its product range for research laboratories and
biopharmaceutical production.
A commercial unit of the UK Medical Research Council (MRC) has
launched a gene-silencing library - based on small interfering RNA
(siRNA) - that covers 90 per cent of the genome of the fruitfly
Drosophila melanogaster which is widely...
Invitrogen has acquired fellow US firm Sequitur in a move that
bolsters its technology portfolio in RNA interference (RNAi) and
marks a continuing trend towards consolidation in this sector.
Dharmacon has entered into a collaboration with fellow US firm
Akceli to explore new ways of conducting high-throughput gene
function analysis, target validation and drug discovery.
An Australian company claims to have successfully achieved the
simultaneous disabling of multiple genes through its RNA
interference (RNAi) technology.
Ambion has developed technique that allows easier monitoring of
short RNA sequences in a variety of sample types and is 100-500
more sensitive than Northern blot analysis.
Research conducted at the European Molecular Biology Laboratory has
suggested that microRNA (miRNA) - small nucleic acid sequences of
20-24 nucleotides that do not code for proteins - in fact play a
key role in gene expression.
CalbaTech has signed an agreement to acquire privately-held
Molecula Research Laboratories, a company developing gene silencing
technologies for gene and protein function studies.
Merck & Co has become the first drug major to make a
significant alliance in the field of RNA interference - one of the
hottest topics in drug discovery - via a deal with Alnylam
Pharmaceuticals.
US antisense specialist Genta has agreed to acquire Salus
Therapeutics, a specialist in small interfering RNA, for up to $30
million in cash and stock. The terms of the agreement call for
Genta to issue $13 million in stock at closing.
Qiagen has reported strong growth in sales and profits in the
second quarter as last year's acquisitions of GenoVision and
Xeragon start to exert their effects. The company has also signed
two new deals in the area of RNA interference.
The battle to amass intellectual property in the hot area of RNA
interference (RNAi) continues to gain pace, with one of the key
players in the category, Alnylam Pharmaceuticals, licensing patents
from the UK's Cambridge Research...
In the second piece of news today on RNAi, Qiagen is to collaborate
with Intradigm on RNAi compounds for use as drug discovery tools
and potential therapeutics.
Exiqon has signed up a new distribution partner, Link Technologies,
for its locked nucleic acid (LNA) phosphoramidate reagents, used in
genomics research.
Alnylam Pharmaceuticals of the USA has linked up with Germany's
Ribopharma to create what it claims is a world leading company in
the development of RNAi-based therapeutics. First drug may be in
trials this year.
A collaboration between Cenix BioScience of Germany and the USA's
Ambion has been formed to co-develop and market the first
commercially-available, human genome-wide library of small
interfering RNA sequences. RNA interference...
Dharmacon, a US supplier of RNA and RNA-interference research
products, announced today it has launched Cell Cycle siARRAY, a
collection of ready-to-use siRNA duplexes designed to knock down
112 genes involved in cell cycle regulation.
